Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report
- PMID: 15961942
- DOI: 10.1159/000085751
Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report
Abstract
Objective: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.
Clinical presentation and intervention: A 50-year-old male with chronic hepatitis C received treatment with alfa-interferon and ribavirin for 52 weeks. He developed immune-mediated diabetes mellitus with low C-peptide and positive antiglutamic acid decarboxylase antibody after completion of therapy. The hepatitis C infection was eradicated, but he continued to be diabetic requiring insulin therapy during the follow-up.
Conclusion: This report shows thatimmune-mediateddiabetes mellitus can occur as a late complication of alfa-interferon therapy.
Copyright (c) 2005 S. Karger AG, Basel.
Similar articles
-
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.Hepatology. 1998 Aug;28(2):341-6. doi: 10.1002/hep.510280208. Hepatology. 1998. PMID: 9695995 Clinical Trial.
-
[Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].Ugeskr Laeger. 2004 Mar 8;166(11):1024-5. Ugeskr Laeger. 2004. PMID: 15049242 Danish. No abstract available.
-
Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.J Drugs Dermatol. 2009 Sep;8(9):870-2. J Drugs Dermatol. 2009. PMID: 19746680
-
[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].Dtsch Med Wochenschr. 1999 May 21;124(20):636-42. doi: 10.1055/s-2007-1024379. Dtsch Med Wochenschr. 1999. PMID: 10370387 Review. German. No abstract available.
-
Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.J Clin Gastroenterol. 2002 Jul;35(1):89-92. doi: 10.1097/00004836-200207000-00019. J Clin Gastroenterol. 2002. PMID: 12080234 Review.
Cited by
-
Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.World J Gastroenterol. 2007 Feb 28;13(8):1292-4. doi: 10.3748/wjg.v13.i8.1292. World J Gastroenterol. 2007. PMID: 17451219 Free PMC article.
-
Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.World J Gastroenterol. 2008 Aug 7;14(29):4713-5. doi: 10.3748/wjg.14.4713. World J Gastroenterol. 2008. PMID: 18698691 Free PMC article.
-
Loss of stress response as a consequence of viral infection: implications for disease and therapy.Cell Stress Chaperones. 2012 Nov;17(6):647-55. doi: 10.1007/s12192-012-0352-4. Epub 2012 Jul 14. Cell Stress Chaperones. 2012. PMID: 22797944 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
